NASDAQ:IMTX Immatics (IMTX) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free IMTX Stock Alerts $9.80 -0.35 (-3.45%) (As of 09:52 AM ET) Add Compare Share Share Today's Range$9.67▼$10.0450-Day Range$10.15▼$12.9452-Week Range$6.46▼$13.16Volume47,541 shsAverage Volume480,126 shsMarket Capitalization$829.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Immatics alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Immatics Stock (NASDAQ:IMTX)Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Read More IMTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMTX Stock News HeadlinesApril 16, 2024 | americanbankingnews.comImmatics (NASDAQ:IMTX) Short Interest UpdateMarch 29, 2024 | markets.businessinsider.comMaintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising PartnershipsApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… March 21, 2024 | investorplace.comIMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023March 21, 2024 | globenewswire.comImmatics Announces Full Year 2023 Financial Results and Corporate UpdateMarch 15, 2024 | finance.yahoo.comWith 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big gunsMarch 10, 2024 | seekingalpha.comCantor sees strong year ahead for oncology M&AMarch 10, 2024 | msn.comCantor Fitzgerald sees strong year ahead for oncology M&AApril 25, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.March 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immatics on Promising TCR-Based Cancer Therapies and Strategic PartnershipsFebruary 28, 2024 | seekingalpha.comEditas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must WatchFebruary 6, 2024 | uk.yahoo.comBolton TV star to 'go back to Fernandos one last time' as he spreads the loveFebruary 3, 2024 | finance.yahoo.comImmatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last yearFebruary 3, 2024 | seekingalpha.comImmatics: Pioneering TCR Therapies In The Fight Against CancerJanuary 17, 2024 | msn.comImmatics commences public offering of sharesJanuary 17, 2024 | finance.yahoo.comImmatics Announces Pricing of $175 Million Public OfferingJanuary 17, 2024 | finance.yahoo.comImmatics Announces Proposed Public OfferingNovember 20, 2023 | markets.businessinsider.comPositive Clinical Progress and Promising Pipeline Underpin Buy Rating for Immatics (IMTX): An Analysis of Graig Suvannavejh’s RecommendationNovember 16, 2023 | markets.businessinsider.comImmatics: Strong Buy Rating Supported by Promising Clinical Results and Upcoming CatalystsNovember 14, 2023 | markets.businessinsider.comImmatics Announces Third Quarter 2023 Financial Results and Business UpdateNovember 8, 2023 | finanznachrichten.deImmatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 TrialNovember 6, 2023 | finance.yahoo.comImmatics (IMTX) Moves 23.2% Higher: Will This Strength Last?November 3, 2023 | nasdaq.comCantor Fitzgerald Initiates Coverage of Immatics N.V (IMTX) with Overweight RecommendationOctober 24, 2023 | finance.yahoo.comImmatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T MonotherapyOctober 12, 2023 | msn.comDown -19.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Immatics (IMTX)October 9, 2023 | seekingalpha.comAnalyzing Immatics' Multi-Faceted Investment CaseSeptember 21, 2023 | finance.yahoo.comIMTX Oct 2023 10.000 putSee More Headlines Receive IMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/25/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IMTX CUSIPN/A CIK1809196 Webwww.immatics.com Phone4.97072E+12FaxN/AEmployees432Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,980,000.00 Net Margins-179.67% Pretax Margin-179.63% Return on Equity-43.58% Return on Assets-22.38% Debt Debt-to-Equity RatioN/A Current Ratio2.87 Quick Ratio2.87 Sales & Book Value Annual Sales$58.44 million Price / Sales14.70 Cash FlowN/A Price / Cash FlowN/A Book Value$2.88 per share Price / Book3.52Miscellaneous Outstanding Shares84,660,000Free FloatN/AMarket Cap$859.30 million OptionableOptionable Beta0.67 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Harpreet Singh Ph.D. (Age 49)CEO, MD, Member of Management Board & Executive Director Comp: $884.46kDr. Toni Weinschenk Ph.D. (Age 50)Co-Founder & Chief Innovation Officer Mr. Arnd Christ MBA (Age 58)Chief Financial Officer Mr. Steffen Walter Ph.D. (Age 47)Chief Operations Officer Mr. Edward A. Sturchio J.D. (Age 48)General Counsel & Secretary Dr. Carsten Reinhardt M.D. (Age 57)Ph.D., Chief Development Officer Mr. Cedrik M. Britten M.D. (Age 48)Chief Medical Officer Mr. Jordan Silverstein (Age 44)Head of Strategy Dr. Hans-Georg Rammensee Ph.D.Co-Founder & Member of the Scientific Advisory BoardMr. Ephraim Hofsäß M.Sc.Vice President of SEC Reporting & AccountingMore ExecutivesKey CompetitorsBioCryst PharmaceuticalsNASDAQ:BCRXKyverna TherapeuticsNASDAQ:KYTXREGENXBIONASDAQ:RGNXRelay TherapeuticsNASDAQ:RLAYCARGO TherapeuticsNASDAQ:CRGXView All CompetitorsInstitutional OwnershipWasatch Advisors LPBought 730,394 shares on 4/18/2024Ownership: 0.863%Wellington Management Group LLPBought 747,772 shares on 3/5/2024Ownership: 7.504%Goldman Sachs Group Inc.Bought 1,183,860 shares on 3/1/2024Ownership: 1.830%Platinum Investment Management Ltd.Bought 45,363 shares on 2/14/2024Ownership: 0.370%ADAR1 Capital Management LLCBought 22,000 shares on 2/14/2024Ownership: 0.026%View All Institutional Transactions IMTX Stock Analysis - Frequently Asked Questions Should I buy or sell Immatics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMTX shares. View IMTX analyst ratings or view top-rated stocks. How have IMTX shares performed in 2024? Immatics' stock was trading at $10.53 at the beginning of 2024. Since then, IMTX shares have decreased by 3.6% and is now trading at $10.15. View the best growth stocks for 2024 here. Are investors shorting Immatics? Immatics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 8,910,000 shares, an increase of 6.2% from the March 15th total of 8,390,000 shares. Based on an average daily trading volume, of 526,500 shares, the short-interest ratio is currently 16.9 days. View Immatics' Short Interest. When is Immatics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our IMTX earnings forecast. How were Immatics' earnings last quarter? Immatics (NASDAQ:IMTX) announced its quarterly earnings results on Thursday, March, 21st. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.09. The firm earned $17.14 million during the quarter, compared to analysts' expectations of $11.78 million. Immatics had a negative trailing twelve-month return on equity of 43.58% and a negative net margin of 179.67%. What ETFs hold Immatics' stock? ETFs with the largest weight of Immatics (NASDAQ:IMTX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Immatics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX), Great Panther Mining (GPL), Idera Pharmaceuticals (IDRA) and Immunic (IMUX). Who are Immatics' major shareholders? Immatics' stock is owned by a number of institutional and retail investors. Top institutional investors include Wasatch Advisors LP (0.86%). How do I buy shares of Immatics? Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMTX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.